These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26031918)

  • 1. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.
    Cho BS; Zeng Z; Mu H; Wang Z; Konoplev S; McQueen T; Protopopova M; Cortes J; Marszalek JR; Peng SB; Ma W; Davis RE; Thornton DE; Andreeff M; Konopleva M
    Blood; 2015 Jul; 126(2):222-32. PubMed ID: 26031918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
    Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ
    Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
    Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M
    Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.
    Chen Y; Jacamo R; Konopleva M; Garzon R; Croce C; Andreeff M
    J Clin Invest; 2013 Jun; 123(6):2395-407. PubMed ID: 23676502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
    Zeng Z; Samudio IJ; Munsell M; An J; Huang Z; Estey E; Andreeff M; Konopleva M
    Mol Cancer Ther; 2006 Dec; 5(12):3113-21. PubMed ID: 17172414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-b Signaling.
    Kim BR; Jung SH; Han AR; Park G; Kim HJ; Yuan B; Battula VL; Andreeff M; Konopleva M; Chung YJ; Cho BS
    Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32629802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
    Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
    Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
    Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
    Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
    Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.
    Tavor S; Eisenbach M; Jacob-Hirsch J; Golan T; Petit I; Benzion K; Kay S; Baron S; Amariglio N; Deutsch V; Naparstek E; Rechavi G
    Leukemia; 2008 Dec; 22(12):2151-5158. PubMed ID: 18769446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists.
    Mandawat A; Fiskus W; Buckley KM; Robbins K; Rao R; Balusu R; Navenot JM; Wang ZX; Ustun C; Chong DG; Atadja P; Fujii N; Peiper SC; Bhalla K
    Blood; 2010 Dec; 116(24):5306-15. PubMed ID: 20810927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
    Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
    Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.
    Sison EA; Magoon D; Li L; Annesley CE; Romagnoli B; Douglas GJ; Tuffin G; Zimmermann J; Brown P
    Oncotarget; 2015 Oct; 6(31):30902-18. PubMed ID: 26360610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
    Sison EA; McIntyre E; Magoon D; Brown P
    Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel dimeric CXCR4 antagonist synergizes with chemotherapy in acute myeloid leukaemia by mobilizing leukaemic cells from their associated bone marrow niches.
    Huang Y; Huang Z; An J; Xu Y
    Br J Haematol; 2019 Oct; 187(1):e11-e15. PubMed ID: 31388999
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells.
    Liesveld JL; Bechelli J; Rosell K; Lu C; Bridger G; Phillips G; Abboud CN
    Leuk Res; 2007 Nov; 31(11):1553-63. PubMed ID: 17403536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia.
    Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H
    J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587.
    Peng SB; Van Horn RD; Yin T; Brown RM; Roell WC; Obungu VH; Ruegg C; Wroblewski VJ; Raddad E; Stille JR
    Oncotarget; 2017 Nov; 8(55):94619-94634. PubMed ID: 29212254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells.
    Kalinkovich A; Tavor S; Avigdor A; Kahn J; Brill A; Petit I; Goichberg P; Tesio M; Netzer N; Naparstek E; Hardan I; Nagler A; Resnick I; Tsimanis A; Lapidot T
    Cancer Res; 2006 Nov; 66(22):11013-20. PubMed ID: 17108140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line.
    Sheng X; Zhong H; Wan H; Zhong J; Chen F
    Exp Ther Med; 2016 Jul; 12(1):396-404. PubMed ID: 27347068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.